Antibody Responses to SARS-CoV-2 Following an Outbreak Among Marine Recruits With Asymptomatic or Mild Infection.
Adolescent
Adult
Antibodies, Neutralizing
/ metabolism
Antibodies, Viral
/ metabolism
Antibody Formation
Asymptomatic Diseases
COVID-19
/ immunology
Cohort Studies
Disease Outbreaks
Disease Progression
Female
Humans
Male
Military Personnel
SARS-CoV-2
/ physiology
Spike Glycoprotein, Coronavirus
/ immunology
United States
/ epidemiology
Young Adult
COVID-19
SARS-COV-2
antibodies
outbreak
young adults
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
16
03
2021
accepted:
19
05
2021
entrez:
28
6
2021
pubmed:
29
6
2021
medline:
6
7
2021
Statut:
epublish
Résumé
We investigated serological responses following a SARS-CoV-2 outbreak in spring 2020 on a US Marine recruit training base. 147 participants that were isolated during an outbreak of respiratory illness were enrolled in this study, with visits approximately 6 and 10 weeks post-outbreak (PO). This cohort is comprised of young healthy adults, ages 18-26, with a high rate of asymptomatic infection or mild symptoms, and therefore differs from previously reported longitudinal studies on humoral responses to SARS-CoV-2, which often focus on more diverse age populations and worse clinical presentation. 80.9% (119/147) of the participants presented with circulating IgG antibodies against SARS-CoV-2 spike (S) receptor-binding domain (RBD) at 6 weeks PO, of whom 97.3% (111/114) remained positive, with significantly decreased levels, at 10 weeks PO. Neutralizing activity was detected in all sera from SARS-CoV-2 IgG positive participants tested (n=38) at 6 and 10 weeks PO, without significant loss between time points. IgG and IgA antibodies against SARS-CoV-2 RBD, S1, S2, and the nucleocapsid (N) protein, as well neutralization activity, were generally comparable between those participants that had asymptomatic infection or mild disease. A multiplex assay including S proteins from SARS-CoV-2 and related zoonotic and human endemic betacoronaviruses revealed a positive correlation for polyclonal cross-reactivity to S after SARS-CoV-2 infection. Overall, young adults that experienced asymptomatic or mild SARS-CoV-2 infection developed comparable humoral responses, with no decrease in neutralizing activity at least up to 10 weeks after infection.
Identifiants
pubmed: 34177926
doi: 10.3389/fimmu.2021.681586
pmc: PMC8220197
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
681586Informations de copyright
At least a portion of this work is authored by Carl Goforth, Dawn L. Weir, Brian L. Pike, James Regeimbal, Mark P. Simons, Michael S. Termini, Stephen Lizewski, Rhonda Lizewski, Eric D. Laing, Christopher C. Broder and Andrew G. Letizia on behalf of the U.S. Government and, as regards Goforth, Weir, Pike, Regeimbal, Simons, Termini, S. Lizewski, R. Lizewski, Laing, Broder, Letizia and the U.S. Government, is not subject to copyright protection in the United States. Foreign and other copyrights may apply.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
N Engl J Med. 2020 Dec 17;383(25):2407-2416
pubmed: 33176093
Trends Immunol. 2006 Jul;27(7):343-8
pubmed: 16731041
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Immunol Rev. 2003 Aug;194:8-18
pubmed: 12846803
Front Immunol. 2019 May 03;10:965
pubmed: 31130955
mBio. 2020 Oct 16;11(5):
pubmed: 33067385
Cell Host Microbe. 2020 May 13;27(5):841-848.e3
pubmed: 32289263
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
Euro Surveill. 2020 Jul;25(28):
pubmed: 32700671
BMJ Mil Health. 2021 Aug;167(4):251-254
pubmed: 32303575
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
J Exp Med. 2006 Oct 30;203(11):2419-24
pubmed: 17030950
Sci Adv. 2020 Nov 6;6(45):
pubmed: 33036961
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
Cell. 2020 Dec 10;183(6):1496-1507.e16
pubmed: 33171099
Front Immunol. 2012 Apr 17;3:78
pubmed: 22566959
Int J Infect Dis. 2020 Sep;98:180-186
pubmed: 32562846
Emerg Infect Dis. 2001 May-Jun;7(3):463-5
pubmed: 11384530
Infect Dis (Lond). 2021 Jul;53(7):498-512
pubmed: 33684020
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Open Forum Infect Dis. 2021 Jan 23;8(2):ofaa654
pubmed: 33553482
Immunity. 2020 Nov 17;53(5):925-933.e4
pubmed: 33129373
Cell Mol Immunol. 2020 Jul;17(7):773-775
pubmed: 32467617
Nat Rev Immunol. 2015 Mar;15(3):160-71
pubmed: 25698678
Sci Rep. 2021 Jan 28;11(1):2608
pubmed: 33510275
Am J Epidemiol. 1989 Feb;129(2):341-8
pubmed: 2912044
Immunity. 1998 Mar;8(3):363-72
pubmed: 9529153
BMJ. 2020 Mar 23;368:m1165
pubmed: 32205334
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
J Infect Dis. 2020 Feb 18;221(5):697-700
pubmed: 30783668
Nat Commun. 2021 Jan 4;12(1):63
pubmed: 33397909
Cell. 2021 Apr 1;184(7):1858-1864.e10
pubmed: 33631096
MMWR Morb Mortal Wkly Rep. 2021 Mar 05;70(9):308-311
pubmed: 33661864
Emerg Infect Dis. 2021 Jan;27(1):
pubmed: 33050983